

Special Issue

G-Protein-Coupled Receptors (GPCRs)

Message from the Guest Editor

G-protein-coupled receptors (GPCRs) are the cell surface protein that constitute the largest family in the human genome (>800gene), and are involved in a wide variety of function in the peripheral and central system. GPCRs have the ability to bind or are activated by multiple ligands, including hormones, photons, ions, neurotransmitters, odorants, peptides, and light, and are involved in the regulation of multiple signaling pathways. The majority of transduction events in cells are under the influence of GPCRs, which is a testament to their significance as a major target of therapeutic drug discovery. Despite recent progress in the field of GPCRs, the structure biology of these surface proteins is poorly understood; however, functional interactions between different GPCRs, including adrenergic, cannabinoid, GABA, dopamine, opioid, and somatostatin receptor subtypes are now well established. As , I invite submission of manuscripts dealing with different aspects of GPCRs for publication in this Special Issue of Biomedicine.

Guest Editor

Prof. Ujendra Kumar

Department of Pharmacology and Toxicology, The University of British Columbia, Vancouver, BC, Canada

Deadline for manuscript submissions

closed (31 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/73942

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).